Izalontamab - CISMeF

Preferred Label : Izalontamab;

NCIt synonyms : EGFR/HER3 Bispecific Antibody SI-B001; HER3 x EGFR SI-B001; Anti-EGFR/anti-HER3 Bi-specific Monoclonal Antibody SI-B001; Anti-EGFR/HER3 Bispecific Antibody SI-B001;

NCIt definition : An immunoglobulin G (IgG) bispecific antibody targeting both the epidermal growth factor receptor (EGFR; HER1; ErbB1) and the epidermal growth factor receptor 3 (HER3; ErbB3), with potential antineoplastic activity. Upon administration, izalontamab simultaneously targets and binds to EGFR and HER3 expressed on cancer cells, thereby preventing receptor phosphorylation. This prevents the activation of both EGFR- and HER3-mediated signaling pathways and results in the inhibition of tumor cell proliferation. EGFR and HER3, both upregulated and/or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation.;

UNII : S8YH2C9NLA;

CAS number : 2559704-24-2; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2559704-24-2 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Molecule name : SI-B001; SI B001;

NCI Metathesaurus CUI : CL1647846;

Details

Origin ID

C178396;

UMLS CUI

C5706701;

Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Epidermal Growth Factor Receptor [NCIt concept]
- Receptor Tyrosine-Protein Kinase erbB-3 [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients